secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001753926-25-001353
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers
--------------------------------------------------------------------------------

- Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.
- Launched ZELSUVMI (berdazimer) on July 10, 2025, first at-home FDA-approved treatment for molluscum contagiosum.
- Built commercial team of 90+ employees including 50 territory sales managers; early orders and prescriptions meeting/exceeding expectations.
- In advanced discussions to acquire a second FDA-approved pediatric infectious disease product.
- Public float ~600k shares; market cap ~$55M (~$165M fully diluted); lockup on Series A Preferred through Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/0001753926-25-001353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/g084926_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer